```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29  PHAR reloaded with new search and display fields
 NEWS  9  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 10  FEB 15  PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15  RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23  KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26  MEDLINE reloaded with enhancements
 NEWS 14  FEB 26  EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26  TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26  IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26  CAS Registry Number crossover limit increased from 10,000
                  to 300,000 in multiple databases
 NEWS 18  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16  CASREACT coverage extended
 NEWS 20  MAR 20  MARPAT now updated daily
 NEWS 21  MAR 22  LWPI reloaded
 NEWS 22  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched
 NEWS 29  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 30  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS 31  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS 32  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS 33  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
 NEWS 34  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                  patents

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
```

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:14:28 ON 06 JUN 2007

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 11:14:43 ON 06 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9
DICTIONARY FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-562128genA.str



chain nodes :
11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-16 7-20 8-11 11-12 11-18 12-13 13-14 14-15 14-19 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
2-16 5-7 6-10 7-8 7-20 8-9 9-10 11-12 11-18 12-13 13-14 14-15 14-19 16-17

exact bonds :
8-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:16:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 227 TO ITERATE

100.0% PROCESSED 227 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3637 TO 5443
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:17:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4076 TO ITERATE

100.0% PROCESSED 4076 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L3 7 SEA SSS FUL L1

=> d scan

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI)

MF C35 H31 F N4 O8

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI)
MF C20 H26 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI)
MF C25 H34 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI)
MF C19 H24 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI)
MF C18 H22 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI)
MF C21 H26 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI)
MF C17 H20 F N3 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 174.80 | 175.01 |

FILE 'CAPLUS' ENTERED AT 11:18:55 ON 06 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 abs ibib hitstr
MISSING OPERATOR L3 ABS
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l3 1-7 abs ibib hitstr
MISSING OPERATOR L3 1-7
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> file caplu

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 2.82 | 177.83 |

FILE 'CAPLUS' ENTERED AT 11:22:34 ON 06 JUN 2007


FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 7 L3

=> d l4 abs ibib hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Process for producing compds. I [X = CR7, N; Y = CR6, N; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form cyclic amino group in cooperation with the adjacent nitrogen.] or their pharmaceutically acceptable salts, characterized by reaction of

compds. II [X, Y, R2-R5 = same as above] or active derivs. thereof with NHR11R12 [R11, R12 = same as above], was provided. For example, to a solution of compound III [R = OH; R' = cyclopentyl] (400 mg) in DMF (5.0 mL) was added 1,1'-carbonyldiimidazole (350 mg) at room temperature, the the reaction was stirred at 100 °C for 20 h. The resulting mixture was treated with Et3N (0.2 mL) and glycine Et ester hydrochloride (180 mg) at room temperature for 5 h to give compound III [R = NHCH2CO2Et; R' = cyclopentyl].

In platelet aggregation inhibition assays, compound III [R = NHCH2CH2P(:O)(OH)2; R' = 2,2-dimethyl-1,3-dioxan-5-yl] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882644 CAPLUS
DOCUMENT NUMBER: 145:292885
TITLE: Quinolone and related compounds as platelet aggregation inhibitors, and process for the preparation thereof
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takahashi, Atsushi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2006225379 | A | 20060831 | JP 2006-9367 | 20060118 |
| PRIORITY APPLN. INFO.: | | | JP 2005-12618 A | 20050120 |

OTHER SOURCE(S): MARPAT 145:292885
IT 836613-50-4P 836617-05-1P 836617-06-2P
836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone and related compds. as platelet aggregation inhibitors)
RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone and related compds. as platelet aggregation

inhibitors)
RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



=> d l4 2-7 abs ibib hitstr

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form a (un)substituted cyclic amino group in cooperation with the adjacent nitrogen; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, -O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, Pd/C catalyzed debenzylation of compound II [R = OCH2Ph] under H2 afforded compound II [R = OH]. In platelet aggregation inhibition assays, compound II [R =

OH] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882641 CAPLUS
DOCUMENT NUMBER: 145:292884
TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Atsushi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2006225378 | A | 20060831 | JP 2006-9349 | 20060118 |
| PRIORITY APPLN. INFO.: | | | JP 2005-12561 A | 20050120 |

OTHER SOURCE(S): MARPAT 145:292884
IT 836613-50-4P 836617-05-1P 836617-06-2P
836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone derivs. as platelet aggregation inhibitors)
RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone derivs. as platelet aggregation inhibitors)
RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB The title compds. (I) and pharmaceutically acceptable salts thereof characterized by each having an amide group at the 3-position which is substituted with a substituent having a carboxylate ester, phosphate ester, sulfate ester or the like, and an amino group at the 7-position which is substituted with a substituent having a ring structure [Y = C-R6; R6 = H, halo, lower alkyl, halo-lower alkyl; R2 = each (un)substituted lower alkyl, cycloalkyl, aryl, or heterocyclyl; R3 = halo; R5 = H, HO, halo; R11 = H, lower alkyl or lower alkyl-amino wherein lower alkyl is optionally substituted; R12 = (un)substituted lower alkyl] are prepared These compds. have excellent P2Y12 (adenine diphosphate receptor) inhibitory effect and platelet agglutination inhibitory effect and consequently are useful as platelet agglutination inhibitors. Thus, hydrogenolysis of [2-(([7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino)ethyl]phosphonic acid dibenzyl ester over 10% Pd-C in MeOH under hydrogen atmospheric for 3 h gave [2-(([7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino)ethyl]phosphonic acid (II). II inhibited ADP-induced aggregation of human blood platelet by 92% at 10 μM and the binding of [3H]-2-MeS-ADP to human P2Y12 by 96% at 30 nM.

ACCESSION NUMBER: 2006:733081 CAPLUS
DOCUMENT NUMBER: 145:188746
TITLE: Preparation of 4-quinolone-3-carboxamide derivatives and salts thereof as platelet aggregation inhibitors
INVENTOR(S): Koga, Yuji; Okuda, Takao; Hirabayashi, Ryoji; Fujiyasu, Jiro; Miyazaki, Takehiro; Watanuki, Susumu; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006077851 | A1 | 20060727 | WO 2006-JP300590 | 20060118 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-12715 A 20050120

OTHER SOURCE(S): MARPAT 145:188746

IT 836621-98-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836621-98-8 CAPLUS

CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 836613-50-4P, [[[7-[(Cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl]amino]acetic acid 836617-05-1P 836617-06-2P 836617-18-6P 836617-19-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836613-50-4 CAPLUS

CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted (hetero)aryl which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; R5 = H, OR2, alkyl, alkenyl, etc.] or II [V, A, X, Z, and U are as defined above; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful in screening and for inducing apoptosis. Over forty synthetic examples showed the synthesis of intermediates and target compds. E.g., a multi-step synthesis of the amide III, starting from 2,3,4,5-tetrafluorobenzoic acid, was given. The title compds. were tested in various tests. For example, they were tested in a stop assay, a high throughput, first-pass screen detecting drugs that bind to and stabilize the target G-quadruplex. E.g., the compound III exhibits approx. 400x selectivity for the c-Myc quadruplex relative to pUC 18 plasmid DNA. III was also tested for antitumor activity (biol. data given). The pharmaceutical composition comprising the compds. I or II is disclosed.

ACCESSION NUMBER: 2006:120542 CAPLUS
DOCUMENT NUMBER: 144:212787
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 558 pp., Cont.-in-part of U.S. Ser. No. 903,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2006029950 | A1 | 20060209 | US 2005-106909 | 20050415 |
| US 7141565 | B1 | 20061128 | US 2004-821243 | 20040407 |
| US 2005085468 | A1 | 20050421 | US 2004-903975 | 20040730 |
| AU 2005325210 | A1 | 20060727 | AU 2005-325210 | 20050729 |
| CA 2575547 | A1 | 20060727 | CA 2005-2575547 | 20050729 |
| WO 2006078317 | A1 | 20060727 | WO 2005-US26977 | 20050729 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1773346 A1 20070418 EP 2005-856890 20050729

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

US 2003-461271P P 20030407
US 2003-463171P P 20030415
US 2003-519535P P 20031112
US 2003-532727P P 20031223
US 2004-821243 A2 20040407
US 2004-903975 A2 20040730
US 2005-106909 A 20050415
WO 2005-US26977 W 20050729

OTHER SOURCE(S): MARPAT 144:212787

IT 783361-99-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS

CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo,

pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

ACCESSION NUMBER: 2005:349002 CAPLUS
DOCUMENT NUMBER: 142:373851
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 453 pp., Cont.-in-part of U.S. Ser. No. 821,243.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2005085468 | A1 | 20050421 | US 2004-903975 | 20040730 |
| US 7141565 | B1 | 20061128 | US 2004-821243 | 20040407 |
| US 2006029950 | A1 | 20060209 | US 2005-106909 | 20050415 |
| AU 2005325210 | A1 | 20060727 | AU 2005-325210 | 20050729 |
| CA 2575547 | A1 | 20060727 | CA 2005-2575547 | 20050729 |
| WO 2006078317 | A1 | 20060727 | WO 2005-US26977 | 20050729 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1773346 | A1 | 20070418 | EP 2005-856890 | 20050729 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| US 2006229303 | A1 | 20061012 | US 2006-390810 | 20060328 |
| US 2007043039 | A1 | 20070222 | US 2006-431602 | 20060510 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2003-461271P | P | 20030407 |
| US 2003-463171P | P | 20030415 |
| US 2003-519535P | P | 20031112 |
| US 2003-532727P | P | 20031223 |
| US 2004-821243 | A2 | 20040407 |
| US 2004-903975 | A2 | 20040730 |
| US 2005-106909 | A | 20050415 |
| WO 2005-US26977 | W | 20050729 |

OTHER SOURCE(S): MARPAT 142:373851
IT 783361-99-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS
CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, etc.; R12 = H, (un)substituted alkyl, etc.; R2 = (un)substituted alkyl, etc.; R3 = halo, etc.; R4 = (un)substituted cycloalkyl, etc.; R5 = H, halo, etc.; R6 = H, halo, etc.; R7 = H, halo, etc.] were prepared For example, hydrogenolysis of compound II [A = OCH2Ph] afforded compound II [A = OH]. In platelet aggregation inhibition assays, compound II [A = OH] exhibited inhibition activity of 92%. Compds. I are claimed useful as platelet aggregation inhibitors, P2Y12 inhibitors.

ACCESSION NUMBER: 2005:99478 CAPLUS
DOCUMENT NUMBER: 142:197896
TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Issei; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2005009971 | A1 | 20050203 | WO 2004-JP10781 | | 20040722 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| JP 2005053903 | A | 20050303 | JP 2004-212326 | | 20040720 |
| CA 2530352 | A1 | 20050203 | CA 2004-2530352 | | 20040722 |
| EP 1650192 | A1 | 20060426 | EP 2004-748045 | | 20040722 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| CN 1826321 | A | 20060830 | CN 2004-80021187 | | 20040722 |
| US 2006148806 | A1 | 20060706 | US 2005-562128 | | 20051223 |
| PRIORITY APPLN. INFO.: | | | JP 2003-278852 | A | 20030724 |
| | | | WO 2004-JP10781 | W | 20040722 |

OTHER SOURCE(S): MARPAT 142:197896

IT 836613-50-4P 836617-05-1P 836617-06-2P
836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)

RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)

RN 836621-98-8 CAPLUS

CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

ACCESSION NUMBER: 2004:902098 CAPLUS
DOCUMENT NUMBER: 141:395565

TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents

INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terrance

PATENT ASSIGNEE(S): Cyclene Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2004091504 | A2 | 20041028 | WO 2004-US11108 | | 20040407 |
| WO 2004091504 | A3 | 20060105 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2004229489 | A1 | 20041028 | AU 2004-229489 | | 20040407 |
| CA 2521810 | A1 | 20041028 | CA 2004-2521810 | | 20040407 |
| EP 1610759 | A2 | 20060104 | EP 2004-759406 | | 20040407 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | | |
| BR 2004009105 | A | 20060425 | BR 2004-9105 | | 20040407 |
| CN 1809572 | A | 20060726 | CN 2004-80014351 | | 20040407 |
| JP 2006522827 | T | 20061005 | JP 2006-509898 | | 20040407 |
| NO 2005004669 | A | 20051114 | NO 2005-4669 | | 20051011 |
| PRIORITY APPLN. INFO.: | | | US 2003-461271P | P | 20030407 |
| | | | US 2003-463171P | P | 20030415 |
| | | | US 2003-519535P | P | 20031112 |
| | | | US 2003-532727P | P | 20031223 |
| | | | WO 2004-US11108 | W | 20040407 |

OTHER SOURCE(S): MARPAT 141:395565

IT 783361-99-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS

CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




=>
Connection closed by remote host